Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination

  1. Joseph J Campo  Is a corresponding author
  2. Timothy Q Le
  3. Jozelyn V Pablo
  4. Christopher Hung
  5. Andy A Teng
  6. Hervé Tettelin
  7. Andrea Tate
  8. William P Hanage
  9. Mark R Alderson
  10. Xiaowu Liang
  11. Richard Malley
  12. Marc Lipsitch
  13. Nicholas J Croucher  Is a corresponding author
  1. Antigen Discovery Inc, United States
  2. University of Maryland, United States
  3. PATH, United States
  4. Harvard TH Chan School of Public Health, United States
  5. Boston Children's Hospital, United States
  6. Imperial College London, United Kingdom

Abstract

Pneumococcal whole cell vaccines (WCVs) could cost-effectively protect against a greater strain diversity than current capsule-based vaccines. Immunoglobulin G (IgG) responses to a WCV were characterised by applying longitudinally-sampled sera, available from 35 adult placebo-controlled phase I trial participants, to a panproteome microarray. Despite individuals maintaining distinctive antibody 'fingerprints', responses were consistent across vaccinated cohorts. Seventy-two functionally distinct proteins were associated with WCV-induced increases in IgG binding. These shared characteristics with naturally immunogenic proteins, being enriched for transporters and cell wall metabolism enzymes, likely unusually exposed on the unencapsulated WCV's surface. Vaccine-induced responses were specific to variants of the diverse PclA, PspC and ZmpB proteins, whereas PspA- and ZmpA-induced antibodies recognised a broader set of alleles. Temporal variation in IgG levels suggested a mixture of anamnestic and novel responses. These reproducible increases in IgG binding a limited, but functionally diverse, set of conserved proteins indicate WCV could provide species-wide immunity.

Data availability

Sequencing data have been deposited in the ENA under accession code ERS2169631. Proteome array data analysed in this study is available as source data files for figures one and two.

The following data sets were generated
The following previously published data sets were used

Article and author information

Author details

  1. Joseph J Campo

    Antigen Discovery Inc, Irvine, United States
    For correspondence
    jcampo@antigendiscovery.com
    Competing interests
    Joseph J Campo, is an employee of Antigen Discovery, Inc.
  2. Timothy Q Le

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Timothy Q Le, is an employee of Antigen Discovery, Inc.
  3. Jozelyn V Pablo

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Jozelyn V Pablo, is an employee of Antigen Discovery, Inc.
  4. Christopher Hung

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Christopher Hung, is an employee of Antigen Discovery, Inc.
  5. Andy A Teng

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Andy A Teng, is an employee of Antigen Discovery, Inc.
  6. Hervé Tettelin

    Institute for Genome Sciences, School of Medicine, University of Maryland, Baltimore, United States
    Competing interests
    No competing interests declared.
  7. Andrea Tate

    PATH, Seattle, United States
    Competing interests
    No competing interests declared.
  8. William P Hanage

    Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard TH Chan School of Public Health, Boston, United States
    Competing interests
    William P Hanage, work on this project was supported by consulting payments from Antigen Discovery, Inc.
  9. Mark R Alderson

    PATH, Seattle, United States
    Competing interests
    No competing interests declared.
  10. Xiaowu Liang

    Antigen Discovery Inc, Irvine, United States
    Competing interests
    Xiaowu Liang, is an employee of Antigen Discovery, Inc. and has an equity interest in Antigen Discovery, Inc.
  11. Richard Malley

    Boston Children's Hospital, Boston, United States
    Competing interests
    Richard Malley, has received honoraria or consulting fees from Merck and Affinivax, and has received research grants through his institution from PATH, the Bill and Melinda Gates Foundation, and Pfizer.
  12. Marc Lipsitch

    Department of Immunology and Infectious Diseases, Harvard TH Chan School of Public Health, Boston, United States
    Competing interests
    Marc Lipsitch, Reviewing editor, eLife, work on this project was supported by consulting payments from Antigen Discovery, Inc, has received honoraria or consulting fees from Pfizer, Affinivax, and Merck, and has received research grants through his institution from Pfizer and PATH.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1504-9213
  13. Nicholas J Croucher

    Department of Infectious Disease Epidemiology, Imperial College London, London, United Kingdom
    For correspondence
    n.croucher@imperial.ac.uk
    Competing interests
    Nicholas J Croucher, work on this project was supported by consulting payments from Antigen Discovery, Inc.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6303-8768

Funding

Bill and Melinda Gates Foundation

  • Joseph J Campo
  • Timothy Q Le
  • Jozelyn V Pablo
  • Christopher Hung
  • Andy A Teng

National Institutes of Health (R01AI066304)

  • Marc Lipsitch

Wellcome (104169/Z/14/Z)

  • Nicholas J Croucher

Royal Society (104169/Z/14/Z)

  • Nicholas J Croucher

PATH

  • Andrea Tate
  • Mark R Alderson

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The VAC-002 phase 1 study (ClinicalTrials.gov identifier: NCT01537185) was reviewed and approved by the Western Institutional Review Board and conducted in compliance with the study protocol, international standards of Good Clinical Practice and the Declaration of Helsinki. Participants were healthy adults aged 18 to 40 years at the time of consent, and had no evidence of chronic health issues, and nor any history of invasive pneumococcal disease or pneumococcal vaccination.

Copyright

© 2018, Campo et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,532
    views
  • 258
    downloads
  • 26
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joseph J Campo
  2. Timothy Q Le
  3. Jozelyn V Pablo
  4. Christopher Hung
  5. Andy A Teng
  6. Hervé Tettelin
  7. Andrea Tate
  8. William P Hanage
  9. Mark R Alderson
  10. Xiaowu Liang
  11. Richard Malley
  12. Marc Lipsitch
  13. Nicholas J Croucher
(2018)
Panproteome-wide analysis of antibody responses to whole cell pneumococcal vaccination
eLife 7:e37015.
https://doi.org/10.7554/eLife.37015

Share this article

https://doi.org/10.7554/eLife.37015

Further reading

    1. Immunology and Inflammation
    Chenchen Mao, Yanyu Chen ... Xiangyang Xue
    Research Article

    The abundance and biological contribution of natural killer (NK) cells in cancer are controversial. Here, we aim to uncover clinical relevance and cellular roles of NK cells in colon cancer liver metastasis (CCLM). Here, we integrated single-cell RNA-sequencing, spatial transcriptomics (ST), and bulk RNA-sequencing datasets to investigate NK cells’ biological properties and functions in the microenvironment of primary and liver metastatic tumors. Results were validated through an in vitro co-culture experiment based on bioinformatics analysis. Useing single-cell RNA-sequencing and ST, we mapped the immune cellular landscape of colon cancer and well-matched liver metastatic cancer. We discovered that GZMK+ resting NK cells increased significantly in tumor tissues and were enriched in the tumor regions of both diseases. After combining bulk RNA and clinical data, we observed that these NK cell subsets contributed to a worse prognosis. Meanwhile, KIR2DL4+ activated NK cells exhibited the opposite position and relevance. Pseudotime cell trajectory analysis revealed the evolution of activated to resting NK cells. In vitro experiments further confirmed that tumor-cell-co-cultured NK cells exhibited a decidual-like status, as evidenced by remarkable increasing CD9 expression. Functional experiments finally revealed that NK cells exhibited tumor-activating characteristics by promoting the dissociation of SCF (stem cell factor) on the tumor cells membrane depending on cell-to-cell interaction, as the supernatant of the co-culture system enhanced tumor progression. In summary, our findings revealed resting NK cells exhibited a clinical relevance with CCLM, which may be exploited for novel strategies to improve therapeutic outcomes for patients with CCLM.

    1. Immunology and Inflammation
    2. Neuroscience
    Yuedan Wang, Ying Li ... Xuan Xiao
    Research Article

    Acute retinal ischemia and ischemia-reperfusion injury are the primary causes of retinal neural cell death and vision loss in retinal artery occlusion (RAO). The absence of an accurate mouse model for simulating the retinal ischemic process has hindered progress in developing neuroprotective agents for RAO. We developed a unilateral pterygopalatine ophthalmic artery occlusion (UPOAO) mouse model using silicone wire embolization combined with carotid artery ligation. The survival of retinal ganglion cells and visual function were evaluated to determine the duration of ischemia. Immunofluorescence staining, optical coherence tomography, and haematoxylin and eosin staining were utilized to assess changes in major neural cell classes and retinal structure degeneration at two reperfusion durations. Transcriptomics was employed to investigate alterations in the pathological process of UPOAO following ischemia and reperfusion, highlighting transcriptomic differences between UPOAO and other retinal ischemia-reperfusion models. The UPOAO model successfully replicated the acute interruption of retinal blood supply observed in RAO. 60 min of Ischemia led to significant loss of major retinal neural cells and visual function impairment. Notable thinning of the inner retinal layer, especially the ganglion cell layer, was evident post-UPOAO. Temporal transcriptome analysis revealed various pathophysiological processes related to immune cell migration, oxidative stress, and immune inflammation during the non-reperfusion and reperfusion periods. A pronounced increase in microglia within the retina and peripheral leukocytes accessing the retina was observed during reperfusion periods. Comparison of differentially expressed genes (DEGs) between the UPOAO and high intraocular pressure models revealed specific enrichments in lipid and steroid metabolism-related genes in the UPOAO model. The UPOAO model emerges as a novel tool for screening pathogenic genes and promoting further therapeutic research in RAO.